WEST CHESTER, PA — Molecular Targeting Technologies, Inc. secured a $3.17 million, five-year National Cancer Institute grant to advance an experimental radiopharmaceutical toward potential clinical testing in patients with non-small …
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.